Exploring brain imaging to understand neurodegeneration in multiple sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the biological mechanisms underlying neurodegeneration in patients with multiple sclerosis (MS) by utilizing multimodal imaging techniques such as MRI and PET-MRI. Participants, who have been part of previous studies for at least eight years, will undergo comprehensive neurological examinations, medical history assessments, neuropsychological testing, and blood sample collection for biobanking. The goal is to enhance understanding of neurodegenerative processes in MS and to identify potential biomarkers for future therapeutic strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Multiple Sclerosis Patient already enrolled in one of those 3 protocols since 8 years or more: INFLASEP, FLUMATEP 1-2 or SHADOWTEP
* Adult patient
* Affiliation to a social security scheme or beneficiary of such a scheme (Except "Aide Médicale d'Etat")
* Consent obtained

Exclusion Criteria:

* Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace maker or the presence of an intra-ocular foreign body (a contra- indication questionnaire will be filled in beforehand)
* Pregnancy, breast-feeding, lack of efficient contraception
* Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases
* Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly)
* Enrolment in another interventional study protocol for the duration of his or her participation without physician's agreement
* Patient under legal protection

Where it's running

• CIC Neurosciences
  Paris, France Recruiting

Study contacts

• Principal investigator: Bruno Stankoff, Pr — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Bruno Stankoff, MD
• Email: bruno.stankoff@aphp.fr
• Phone: 1 42 16 24 32

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases

  This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.

  Recruiting Phase 1 Tongji Hospital · Wuhan, Hubei · NCT07526493

• Can QSM MRI help tell MS from age-related brain changes in older adults

  This study tests whether an advanced MRI technique called QSM can better differentiate MS-related brain lesions from age-related or small vessel changes in people aged 50–70.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07444047

• Escalation versus induction therapy for relapsing MS starting after age 50

  This project will test whether starting with stronger, highly effective treatments or beginning with moderate drugs and escalating later changes the risk of inflammatory relapses for people whose relapsing MS began after age 50.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07313462

• Impact of a Palliative Care Model on Patient Knowledge and Attitudes

  This study tests if a video about palliative care can help people with Multiple Sclerosis understand their treatment options better than just reading a pamphlet.

  Recruiting at 2 sites Hunter College of City University of New York · New York, New York and 1 other locations · NCT06860932

• Observational study on CNS inflammatory demyelinating diseases in the Chinese population

  This study is looking to understand how certain brain diseases, like Multiple Sclerosis, affect people in China and what factors might influence their progression and treatment.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06541626

• C-CAR168 treatment for autoimmune diseases not responding to standard therapy

  This study is testing a new treatment called C-CAR168 to see if it can help adults with autoimmune diseases that haven't improved with standard therapies.

  Recruiting Phase 1 RenJi Hospital · Shanghai, Shanghai Municipality · NCT06249438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.